CD274 and neoplasm: Since the IHC-based measurement relies on static and limited biopsy sampling, it often proves inadequate for monitoring PD-L1 levels throughout the entire tumor over time, thereby failing to capture the PD-L1 heterogeneity across multiple patients (15–20).